Regeneron Pharmaceuticals Inc at Cowen Health Care Conference (Virtual) Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Tyler Martin Van Buren - Cowen and Company, LLC, Research Division - Analyst : Fantastic. Thanks very much for that introduction, Bob. Before I get started, I want to also mention to the audience that you can submit questions by the web portal or e-mail me at tyler and I'll do my best to get it asked. Now with that, let's go ahead and start with EYLEA given the recent Bambismo launch. EYLEA has been absolutely bulletproof since its launch. On the other hand, we've got survey results that will show the panel tomorrow morning that show that physicians are expecting a significant decline over the next 5 years. So I know you're not counter detailing per se, but can you remind us what kind of commercial tactics you're able to deploy as the vismo launches here?

Question: Tyler Martin Van Buren - Cowen and Company, LLC, Research Division - Analyst : Great. So the recent Phase II CANDELA presentation at Angiogenesis highlighted the durable -- potentially durable drying benefit of the high-dose. EYLEA also showed encouraging retinal thickness and visual acuity results up to 44 weeks, with 52% specifically, being maintained without requiring PRN or rescue treatment. So in the Phase III PHOTON and PULSAR studies that are reading out later in the year, is the goal essentially to replicate this and to maintain 50% patients up to 12 weeks or greater? Or what are the goals of those trials?

Question: Tyler Martin Van Buren - Cowen and Company, LLC, Research Division - Analyst : Okay. Great. Thanks for that, Neil. Let's maybe move to Dupixent. The product continues to be an absolute beast. So can you give us a sense of the breakdown of sales in the currently approved indications between AD, asthma and CRS with nasal polyps. And how do you expect that to change over the next 5 years?

Question: Tyler Martin Van Buren - Cowen and Company, LLC, Research Division - Analyst : Okay. And in terms of the emerging expansion opportunities, whether it's EoE, PN, or CSU. I'm assuming it's going to be EoE or PN, but which is the most exciting to you?

Question: Tyler Martin Van Buren - Cowen and Company, LLC, Research Division - Analyst : Okay. That's good to hear. In terms of the Amgen's test fire launch, how significant of an impact do you expect that to have with dupi in asthma?

Question: Tyler Martin Van Buren - Cowen and Company, LLC, Research Division - Analyst : Okay. Great. Let's move to the COVID antibody front. So related to the development of the next-gen antibodies that went into the clinic in the coming months, you stated that they'll be active against all current previous and potential future variants of concerns. So can you elaborate on how this is possible? I'm assuming you're targeting conserved regions like Sotrovimab, but would love to hear more about the strategy.

Question: Tyler Martin Van Buren - Cowen and Company, LLC, Research Division - Analyst : Can you give us -- I understand you may just finish your discussions with regulatory authorities, but can you give us any general sense in what a trial nowadays might look like? Is it dependent on another variant wave to come? And when these next-gen antibodies could potentially reach the market?

Question: Tyler Martin Van Buren - Cowen and Company, LLC, Research Division - Analyst : Got it. All right. Now let's move to Libtayo. The Dermato oncology launches continue to go well. But do you expect to make significant progress throughout the year in the initial approved lung cancer indication of BDL1 high patients? Or will we need to wait for the chemo combo group in September?

Question: Tyler Martin Van Buren - Cowen and Company, LLC, Research Division - Analyst : Thinking about the chemo-combo launch, obviously, being 1 of 2 drugs in a very large market is still a pretty great situation. But more specifically, how do you plan to compete with KEYTRUDA? Are you guys going to be speaking towards or marketing to the improvement that you saw in the squam patient population and the numerical improvement? Or how do you expect to compete?

Question: Tyler Martin Van Buren - Cowen and Company, LLC, Research Division - Analyst : It's a great segue into the bispecific pipeline. So -- but it is a very competitive space that I think KOLs would argue still is relatively undifferentiated. So how do you expect to differentiate yourselves from here on out?

Question: Tyler Martin Van Buren - Cowen and Company, LLC, Research Division - Analyst : Okay. And on the solid tumor front, what bispecific programs are you most excited about? And when should we expect the next data readouts from those? I believe we should be getting some potentially later this year.

Question: Tyler Martin Van Buren - Cowen and Company, LLC, Research Division - Analyst : Just as a follow-up, are ADCs modality that you guys might look to explore more broadly, obviously, historically, you guys haven't had a lot of ADC programs.

Question: Tyler Martin Van Buren - Cowen and Company, LLC, Research Division - Analyst : How many different tumor types can you go after with that program?

Question: Tyler Martin Van Buren - Cowen and Company, LLC, Research Division - Analyst : Okay. So I wanted to go to Regeneron Genetics medicines. It seems to be an increasing focus for Regeneron in partnership with Alnylam, Decibel, Intellia, who just reported positive data, as Bob mentioned. You've listed 10 pre-IND and clinical development programs with another 30-plus in research and candidate selection phase. So I guess, do you expect to put as much effort into this aspect or emerging aspect of the business as you do with oncology? And as we look out to 2030 and beyond, should -- do you expect it to be a similar size? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. MARCH 08, 2022 / 6:30PM, REGN.OQ - Regeneron Pharmaceuticals Inc at Cowen Health Care Conference (Virtual)

Question: Tyler Martin Van Buren - Cowen and Company, LLC, Research Division - Analyst : Great. I have a question from the audience, not sure to what extent you can answer it. But basically asking what plans you guys have for rapid responses against other potential pandemic viruses apart from SAR-CoV2.

Question: Tyler Martin Van Buren - Cowen and Company, LLC, Research Division - Analyst : Very interesting, too. So to wrap up, I want to ask both of you, Bob and Neil, what aspect of the Regeneron story do you believe is most underappreciated by investors?

Question: Tyler Martin Van Buren - Cowen and Company, LLC, Research Division - Analyst : Yes. We're up on time. Bob and Neil, thank you very much. It's a privilege to have you here. And everyone, have a great day.